Update on CAR T cell therapies at CICON18
With all the furore and excitement over Dr Jim Allison’s Nobel prize award that hit CICON18 on Monday, it would be fair to say it was the highlight of the conference for many and it was pretty cool to be there in New York at the time.
Aside from the external news, there were also some intriguing developments to report on the CAR T cell therapy front – you might be forgiven for thinking that there’s not much new to say with two products now approved, but I have to point out that this is a very active area of research and there’s much going on here that is well worth highlighting.
Cell therapy is a bit like the twilight zone in the city that never sleeps – there’s a different vibe and energy about this particular research niche in oncology and quite a few new developments to discuss…
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This content is restricted to subscribers